The Alpha Genesis Primate Research Center (AGPRC), the Research Division of Alpha Genesis Incorporated (AGI), is to take on additional European business commitments as the firm continues its expansion efforts on the continent.
AGPRC (Yemassee, South Carolina, USA) is the designated Contract Research Organization (CRO) of Alpha Genesis Incorporated (AGI). The AGPRC research team is dedicated to fighting diseases ranging from Alzheimer’s to Zika and seeks to substantially improve human and animal health worldwide. In partnership with government organizations, private foundations, and private industry, AGPRC conducts studies seeking breakthrough discoveries of causes, preventions, treatments and cures. The highly regulated study of nonhuman primates is critically important, as it often precedes clinical trials in humans and cannot be replicated any other way.
The move is expected to see AGI’s European research business increase by over 75 percent to in excess of $4 million per annum over the next 18 months. The main lines being considered are contract research projects with rhesus and cynomolgus macaques to accommodate explosive demand for work with nonhuman primates across Europe.
Furthermore, a number of AGI’s customers based in countries which support Big-Pharma such as France, Switzerland and the Netherlands will move an increased portion of their studies to AGI’s European outreach operation in 2019.
“This is an excellent opportunity to combine our talents and capitalise fully on the strength of Europe’s Primate Research Markets and is a further step in our overall strategy to be a leading provider of primate research services for European Pharma. Our investment of over $2 million in staff and infrastructure has allowed us to make significant inroads across this highly competitive area, ” commented Greg Westergaard, Ph.D., AGI
Alpha Genesis is a leading life sciences company that provides primates and primate research services worldwide.